H.C. Wainwright raises Nurix stock price target on strong revenue
H.C. Wainwright raised its price target for Nurix Therapeutics (NASDAQ:NRIX) to $36, citing strong Q3 2026 results with $673.1M in revenue and $4.73 EPS. The firm noted increased expenses due to a Roche transaction but highlighted $1.1B in cash reserves. Analysts have mixed views on NRIX's growth potential, with price targets ranging from $33 to $41.
How this was made
The 30-second read
Why it matters
Analyst upgrades signal short‑term upside, but higher expenses may temper longer‑term expectations.
Market read
Nurix's earnings beat and higher guidance drive a positive bias for the stock, with potential spillover to biotech peers.
What to watch
Cash burn from increased SG&A and reliance on collaboration revenue could constrain long‑term profitability.
Background
The article summarizes analyst price‑target revisions following Nurix Therapeutics' Q3 fiscal 2026 earnings release.
Ticker impact
H.C. Wainwright raised its price target on Nurix Therapeutics to $36, citing Q3 fiscal 2026 earnings with $673.1M collaboration revenue and a net gain of $4.73 per share.
likely upward pressure as the market prices in higher earnings expectations and raised price targets
Multiple analysts increased targets after fresh earnings data, indicating improved growth outlook.
Market effects
Biotech sector may see modest rally as earnings beat and higher guidance lift sentiment.
U.S. biotech investors could increase exposure to NRIX and peers.
Limited to investors tracking U.S. biotech earnings; no broader macro effect.
Counterpoint
Some investors may view the raised targets as overoptimistic given higher SG&A expenses.
Key entities
- companyNurix Therapeutics Inc.
Biotech firm reporting Q3 fiscal 2026 results.
- analystH.C. Wainwright
Raised price target to $36.
